VivoSeq
Other

Glucose Intolerance

17

Pipeline Programs↗

3

Active Trials↗

14

Companies Involved↗

Glucose intolerance is an emerging landscape with 17 programs across 14 companies. The most active players are EMD Serono, Danco, Eli Lilly. 5 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

0/100

Mech. Concentration

17/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

EMD Serono logo

EMD Serono

1 program

Phase 1D

Danco

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2GSK logo

GSK

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 3Pfizer logo

Pfizer

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

94%

Small molecule

15 of 16 classified programs — the dominant modality here.

6%ALL OTHERSPeptide16%

Small molecule leads; the ring shows all 16 classified programs, each share of the total. Modality classified for 89% of 18 pipeline programs.

Analysis

Trial Status

11

clinical trials

Completed5 · 45%
Unknown status3 · 27%
Recruiting3 · 27%

Clinical Trials

Trial Activity

11 trials

Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients
Recruiting·UUniversity of Colorado, Denver·Phase 1·NCT05515978·100 enrolled
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
Recruiting·UUniversity of Pennsylvania·Phase 2·NCT04731272·30 enrolled
Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes: a Double Blind RCT
Recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 3·NCT05569772·252 enrolled
Comparison of Eplerenone Versus Spironolactone in Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes
Completed·MMontreal Heart Institute·Phase 3·NCT01586442·62 enrolled
Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance
Completed·NNagoya University·Phase 4·NCT00129233·1,150 enrolled
Is Insulin Resistance and/or Glucose Intolerance Pathogenetic in the Development of a Reduced Incretin Effect
Completed·UUniversity Hospital, Gentofte, Copenhagen·N/A·NCT00784745·21 enrolled
Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes
Completed·National Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00064727·50 enrolled
Mifepristone Effects on Glucose Intolerance in Obese/Overweight Adults
Completed·Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 1/2·NCT01419535·19 enrolled
Probiotics (Lactobacillus Rhamnosus) in Reducing Glucose Intolerance During and After Pregnancy
Unknown status·—·Phase 3·NCT01436448·200 enrolled
Prevention of Corticosteroid-induced Glucose Intolerance
Unknown status·HHadassah Medical Organization·Phase 3·NCT00240604·100 enrolled
Effect of UDCA on the New Onset Diabetes and Glucose Intolerance Induced by Statin
Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 2/3·NCT05500937·1,000 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)